Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
29.50
+0.78 (2.72%)
At close: Jan 21, 2026, 4:00 PM EST
30.09
+0.59 (2.00%)
After-hours: Jan 21, 2026, 5:50 PM EST
Stoke Therapeutics Employees
Stoke Therapeutics had 128 employees as of December 31, 2024. The number of employees increased by 18 or 16.36% compared to the previous year.
Employees
128
Change (1Y)
18
Growth (1Y)
16.36%
Revenue / Employee
$1,606,500
Profits / Employee
$316,930
Market Cap
1.68B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 128 | 18 | 16.36% |
| Dec 31, 2023 | 110 | -7 | -5.98% |
| Dec 31, 2022 | 117 | 15 | 14.71% |
| Dec 31, 2021 | 102 | 23 | 29.11% |
| Dec 31, 2020 | 79 | 23 | 41.07% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MannKind | 407 |
| Biohaven | 256 |
| Celldex Therapeutics | 186 |
| Tango Therapeutics | 155 |
| Kodiak Sciences | 109 |
| Pharvaris | 108 |
| Definium Therapeutics | 74 |
| Enliven Therapeutics | 62 |
STOK News
- 5 days ago - Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
- 6 days ago - Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's Opportunity - Seeking Alpha
- 10 days ago - Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome - Business Wire
- 15 days ago - Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 6 weeks ago - Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting - Business Wire
- 7 weeks ago - Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting - Business Wire
- 2 months ago - Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments - Business Wire
- 2 months ago - Stoke Therapeutics to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference - Business Wire